文献速递认知障碍与痴呆帕金森病与运动障碍

血浆磷酸化tau217在皮质基底节综合征患者中鉴别阿尔茨海默病与额颞叶变性亚型的评估

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项多队列研究纳入皮质基底节综合征(CBS)、进行性核上性麻痹Richardson综合征(PSP-RS)和非流畅性原发性进行性失语(nfvPPA)患者,验证血浆p-tau217对PET证实的阿尔茨海默病(AD)病理的鉴别能力。CBS中p-tau217对Aβ PET的AUC为0.87、对FTP PET的AUC为0.93,PSP-RS和nfvPPA相对对照无升高。

要点

  • CBS中血浆p-tau217鉴别Aβ PET阳性的AUC为0.87(95%CI 0.76-0.98,P<.001)。
  • CBS中血浆p-tau217鉴别FTP PET阳性的AUC为0.93(95%CI 0.83-1.00,P<.001)。
  • PSP-RS和nfvPPA的血浆p-tau217相对对照无升高。

核心结论

  • 在该队列研究中,血浆p-tau217对识别CBS内Aβ或FTP PET阳性(可能潜在AD病理)具有极好的诊断性能。
  • 血浆p-tau217可能是一种有用且廉价的生物标志物,用于为CBS临床试验筛选患者。

研究设计与样本

  • 多队列研究,随访6、12和24个月,2011年1月至2020年9月从4RT神经影像倡议(4RTNI)的8个三级中心招募成年参与者。
  • 纳入CBS(n=113)、PSP-RS(n=121)和nfvPPA(n=39)患者;其他诊断因罕见被排除(n=29)。
  • 在加州大学旧金山分校评估PET证实的AD个体(n=54)和PET阴性认知正常对照(n=59);操作者对队列设盲。
  • 血浆p-tau217通过Meso Scale Discovery电化学发光法测量,对照Aβ和flortaucipir(FTP)PET进行验证。

主要发现

  • 386名参与者中199名(52%)为女性,平均(SD)年龄68(8)岁。
  • CBS伴Aβ PET阳性者血浆p-tau217平均(SD)为0.57(0.43)pg/mL,CBS伴FTP PET阳性者为0.75(0.30)pg/mL,与AD对照的0.72(0.37)pg/mL浓度相当。
  • PSP-RS和nfvPPA相对对照未见血浆p-tau217升高。
  • CBS中p-tau217对Aβ PET的AUC为0.87(95%CI 0.76-0.98;P<.001),对FTP PET的AUC为0.93(95%CI 0.83-1.00;P<.001)。
  • 基线时,以PET验证的血浆p-tau217 cutoff≥0.25 pg/mL定义的CBS-AD个体(n=12)较CBS-FTLD个体(n=39)有更明显的颞顶叶萎缩,而纵向CBS-FTLD个体脑干萎缩速率更快;CBS-FTLD在改良PSP评定量表上进展较CBS-AD更快(平均[SD] 3.5[0.5] vs 0.8[0.8]分/年;P=.005)。

关键数值与推荐

  • CBS中血浆p-tau217鉴别Aβ PET阳性的AUC为0.87(95%CI 0.76-0.98;P<.001)。
  • CBS中血浆p-tau217鉴别FTP PET阳性的AUC为0.93(95%CI 0.83-1.00;P<.001)。
  • PET验证的血浆p-tau217 cutoff为≥0.25 pg/mL。

临床怎么用

  • 作者认为血浆p-tau217可能是一种有用且廉价的生物标志物,用于为CBS临床试验筛选患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Plasma phosphorylated tau217 (p-tau217), a biomarker of Alzheimer disease (AD), is of special interest in corticobasal syndrome (CBS) because autopsy studies have revealed AD is the driving neuropathology in up to 40% of cases. This differentiates CBS from other 4-repeat tauopathy (4RT)-associated syndromes, such as progressive supranuclear palsy Richardson syndrome (PSP-RS) and nonfluent primary progressive aphasia (nfvPPA), where underlying frontotemporal lobar degeneration (FTLD) is typically the primary neuropathology. OBJECTIVE: To validate plasma p-tau217 against positron emission tomography (PET) in 4RT-associated syndromes, especially CBS. DESIGN, SETTING, AND PARTICIPANTS: This multicohort study with 6, 12, and 24-month follow-up recruited adult participants between January 2011 and September 2020 from 8 tertiary care centers in the 4RT Neuroimaging Initiative (4RTNI). All participants with CBS (n = 113), PSP-RS (n = 121), and nfvPPA (n = 39) were included; other diagnoses were excluded due to rarity (n = 29). Individuals with PET-confirmed AD (n = 54) and PET-negative cognitively normal control individuals (n = 59) were evaluated at University of California San Francisco. Operators were blinded to the cohort. MAIN OUTCOME AND MEASURES: Plasma p-tau217, measured by Meso Scale Discovery electrochemiluminescence, was validated against amyloid-β (Aβ) and flortaucipir (FTP) PET. Imaging analyses used voxel-based morphometry and bayesian linear mixed-effects modeling. Clinical biomarker associations were evaluated using longitudinal mixed-effect modeling. RESULTS: Of 386 participants, 199 (52%) were female, and the mean (SD) age was 68 (8) years. Plasma p-tau217 was elevated in patients with CBS with positive Aβ PET results (mean [SD], 0.57 [0.43] pg/mL) or FTP PET (mean [SD], 0.75 [0.30] pg/mL) to concentrations comparable to control individuals with AD (mean [SD], 0.72 [0.37]), whereas PSP-RS and nfvPPA showed no increase relative to control. Within CBS, p-tau217 had excellent diagnostic performance with area under the receiver operating characteristic curve (AUC) for Aβ PET of 0.87 (95% CI, 0.76-0.98; P < .001) and FTP PET of 0.93 (95% CI, 0.83-1.00; P < .001). At baseline, individuals with CBS-AD (n = 12), defined by a PET-validated plasma p-tau217 cutoff 0.25 pg/mL or greater, had increased temporoparietal atrophy at baseline compared to individuals with CBS-FTLD (n = 39), whereas longitudinally, individuals with CBS-FTLD had faster brainstem atrophy rates. Individuals with CBS-FTLD also progressed more rapidly on a modified version of the PSP Rating Scale than those with CBS-AD (mean [SD], 3.5 [0.5] vs 0.8 [0.8] points/year; P = .005). CONCLUSIONS AND RELEVANCE: In this cohort study, plasma p-tau217 had excellent diagnostic performance for identifying Aβ or FTP PET positivity within CBS with likely underlying AD pathology. Plasma P-tau217 may be a useful and inexpensive biomarker to select patients for CBS clinical trials.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. VandeVrede L, La Joie R, Thijssen EH, et al. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome. JAMA Neurol. 2023. PMID: 37010841. doi:10.1001/jamaneurol.2023.0488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。